Investigational drug · Phase 3
Cetrelimab
Also called: JNJ-63723283
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
7 still active
All registered trials
20
Any phase or sponsor naming "Cetrelimab"
First trial start
2016
Nov 21, 2016
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Cetrelimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Urinary Bladder Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Neoplasms
- Urothelial Carcinoma
- Prostatic Neoplasms, Castration-Resistant
- Bladder Cancer
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Cetrelimab" as an intervention, largest first.
- A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)Pivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05714202 · 1,135 participants · Start Mar 23, 2023 · Primary completion Sep 18, 2029
Drug: TAR-200; Cetrelimab and 1 more · For: Bladder Cancer
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Long Beach, California · 240 sites in all
- A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04658862 · 518 participants · Start Dec 7, 2020 · Primary completion Dec 30, 2026
Drug: Cetrelimab; TAR-200 and 2 more · For: Urinary Bladder Neoplasms
Sites: Loma Linda, California; Los Angeles, California; Santa Monica, California · 290 sites in all
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05818683 · 300 participants (planned) · Start Apr 26, 2023 · Primary completion Aug 31, 2027
Drug: Pasritamig; Cetrelimab and 8 more · For: Metastatic Castration-resistant Prostate Neoplasms; Metastatic Hormone-sensitive Prostate Cancer
Sites: Sarasota, Florida; Grand Rapids, Michigan; Brooklyn, Mississippi · 15 sites in all
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced CancersActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT02908906 · 234 participants · Start Nov 21, 2016 · Primary completion Nov 17, 2023
Drug: JNJ-63723283 · For: Neoplasms
Sites: St Louis, Missouri; Pittsburgh, Pennsylvania; Chisinau, Moldova · 20 sites in all
- A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical CystectomyPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04640623 · 220 participants · Start Dec 18, 2020 · Primary completion Jul 3, 2025
Drug: TAR-200; Cetrelimab · For: Urinary Bladder Neoplasms
Sites: Tucson, Arizona; Los Angeles, California; Sherman Oaks, California · 144 sites in all
- A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the BladderPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04919512 · 163 participants · Start Jul 7, 2022 · Primary completion Feb 4, 2025
Drug: TAR-200; Cetrelimab · For: Urinary Bladder Neoplasms
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 109 sites in all
- A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03431350 · 136 participants · Start Mar 2, 2018 · Primary completion Aug 31, 2021
Drug: Niraparib 200 mg; Cetrelimab 240 mg and 3 more · For: Prostatic Neoplasms, Castration-Resistant
Sites: Tucson, Arizona; Denver, Colorado; Jacksonville, Florida · 50 sites in all
Johnson & Johnson Enterprise Innovation Inc.Johnson & Johnson (Janssen) (JNJ)
NCT06311578 · 126 participants (planned) · Start Apr 10, 2024 · Primary completion Nov 8, 2028
Drug: JNJ-87704916; Cetrelimab and 1 more · For: Neoplasms
Sites: New York, New York; Philadelphia, Pennsylvania; Pittsburgh, Pennsylvania · 10 sites in all
- A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial CancerPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03473743 · 125 participants · Start Apr 5, 2018 · Primary completion Sep 30, 2022
Drug: Erdafitinib; Cetrelimab and 2 more · For: Urothelial Carcinoma
Sites: Aurora, Colorado; Louisville, Kentucky; Rockville, Maryland · 127 sites in all
- Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate CancerPivotal-lookingActive, not recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT04592237 · 120 participants (planned) · Start Dec 29, 2020 · Primary completion Dec 31, 2027
Drug: Cabazitaxel; Carboplatin and 2 more · For: Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma and 3 more
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- A Randomized, Double-Blind, Placebo-Controlled Study of the PD-1 Inhibitor Cetrelimab in Chronic Hepatitis B.
Asselah T, Kakuda TN, Kulke S, et al. · J Viral Hepat 2026
- Can manual gemcitabine instillation or tumor microenvironment-based selection enhance the efficacy of TAR-200 in bladder cancer?
Chen L, Liang C · Transl Oncol 2026
- Re: Andrea Necchi, Félix Guerrero-Ramos, Paul L. Crispen, et al. Gemcitabine Intravesical System plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Patients with MIBC: Primary Analysis and Biomarker Results of SunRISe-4. J Clin Oncol. In press. https://doi.org/10.1200/JCO-25-02382.
Di Lorenzo G, Buonerba C · Eur Urol Oncol 2026
- A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies.
Rutkowski P, Kowalski DM, Moreno V, et al. · Cancer Immunol Immunother 2026
- Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study.
Loriot Y, Powles T, Moreno V, et al. · J Clin Oncol 2026
- Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab.
Di Lorenzo G, Di Maio M, Buonerba C · Oncol Ther 2026
Also in development for Urinary Bladder Neoplasms
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- TAR-200JNJ-17000139, Gemcitabine-Releasing Intravesical SystemPhase 35 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Bladder Cancer
- VepugratinibLY3866288Phase 32 trials
Eli Lilly · Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3
- MK-3120SKB410Phase 24 trials
Merck & Co. · Bladder Cancer, Advanced Solid Tumors, Malignant Neoplasm
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.